24.48
Nektar Therapeutics (NKTR) 最新ニュース
What drives Nektar Therapeutics stock priceBreakout profit opportunities - Autocar Professional
What analysts say about Nektar Therapeutics stockExceptional profit velocity - jammulinksnews.com
Nektar Therapeutics Stock Analysis and ForecastHigh-return market picks - Autocar Professional
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam - MSN
Is Nektar Therapeutics a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin - MSN
Why Nektar Therapeutics Stock Dived by 3% Today - AOL.com
Nektar Therapeutics Announces Pricing of $100 Million Public Offering - 富途牛牛
B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi - Barchart.com
Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis - AJMC
5 Second-Half Biopharma Milestones To Watch - BioSpace
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial - MSN
Nektar Therapeutics Announces Closing of $115 Million Public Off - GuruFocus
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - WV News
Nektar Raises $115M in Oversubscribed Offering: Major Boost for Immunotherapy Drug Development - Stock Titan
Nektar Therapeutics Prices $100 Million Common Stock Offering - MarketScreener
Nektar Therapeutics launches proposed public offering - MSN
Nektar Therapeutics Announces Pricing of $100 Million Public Off - GuruFocus
Nektar Therapeutics (NKTR) Launches Public Offering - GuruFocus
Nektar Therapeutics (NKTR) Stock Dips Amid $100M Offering - GuruFocus
Nektar Therapeutics dips after announcing equity offering - TradingView
Nektar Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Nigeria
Nektar Therapeutics Announces Proposed Public Offering | NKTR Stock News - GuruFocus
Nektar Therapeutics Announces Proposed Public Offering - WV News
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView
Immunotherapy Developer Nektar Therapeutics Announces Major Stock Offering to Fuel Clinical Pipeline - Stock Titan
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? - The Globe and Mail
REZOLVE-AD and Rezpegaldesleukin for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH - HCPLive
Nektar eyes pivotal trials for eczema drug cast off by Lilly - pharmaphorum
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside - MSN
Why Nektar Therapeutics Stock Was Red-Hot Today - MSN
Nektar Therapeutics Leads Stock Market Frenzy With Impressive Gains - Finimize
Nektar Therapeutics' REZPEG: A Paradigm Shift in Dermatology and a Catalyst for a Biotech Turnaround - AInvest
Nektar (NKTR) Receives Significant Price Target Upgrade | NKTR S - GuruFocus
Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? - TipRanks
大文字化:
|
ボリューム (24 時間):